Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
FDA drug recalls in 2023
Every FDA drug recall initiated in 2023, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
1,122 recalls, newest first.
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin and Sulbactam for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ampicillin for Injection
Lack of Assurance of Sterility
Class II · Moderate risk
Ascorbic Acid Preserved Injection Solution
Mislabeling: preservative free product labeled as preserved.
Class II · Moderate risk
Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL Vial
Sub-potent Drug
Class II · Moderate risk
Lorazepam Injection
Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C.
Class II · Moderate risk
HYDROmorphone HCl 10 mg in 0.9% Sodium Chloridge
CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
Class II · Moderate risk
buPROPrion Hydrochloride Extended-Release Tablets
Failed Dissolution Specifications; during stability testing